By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today reported a 13 percent jump in revenues for the fourth quarter of 2010 to $483.6 million, compared to $428.8 million a year ago, and exceeding consensus analyst estimates of $464.83.

Driving revenues for the three months ended Dec. 31, 2010, was an increase in uptake of the company's new systems, continued expansion in Asia, and an improved overall economy, Douglas Berthiaume, chairman and CEO of Waters, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.